Physician profile
Danielle Ali
NPI 1437509130
$1,853.37
in general payments reported to CMS, 2019-2025
12 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $200 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $499.32 | 2025 | Ozempic, Wegovy, Rybelsus |
| Phathom Pharmaceuticals, INC. | $186.71 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $157.92 | 2025 | Austedo Xr |
| Sun Pharmaceutical Industries INC. | $142.21 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $134.90 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Gilead Sciences, INC. | $127.86 | 2025 | Descovy |
| Neuronetics, INC. | $113.47 | 2025 | Neurostar Tms Therapy System |
| Pfizer INC. | $102.62 | 2024 | |
| Neurelis, INC. | $101.43 | 2025 | Valtoco |
| Glaxosmithkline, LLC. | $101.14 | 2025 | Nucala |
| Cipher Pharmaceuticals US LLC | $99.12 | 2025 | Natroba, Spinosad |
| Kyowa Kirin, INC. | $86.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.